18F-FDG-PET/CT in initial staging and assessment of early response to chemotherapy of pediatric rhabdomyosarcomas

Nuclear Medicine Communications

Volumn 33, Issue 10, 2012, Pages 1089-1095

  Eugene, Thomas ^a   Corradini, Nadege ^a   Carlier, Thomas ^a   Dupas, Benoit ^a   Leux, Christophe ^a   Bodet Milin, Caroline ^a  

^a NANTES UNIVERSITY HOSPITAL   (France)

Author keywords

18F FDG PET; pediatric oncology; rhabdomyosarcoma; staging; therapeutic response

Indexed keywords

ANTINEOPLASTIC AGENT; FLUORODEOXYGLUCOSE F 18; DIAGNOSTIC AGENT;

ARTICLE; BONE METASTASIS; BONE SCINTISCANNING; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CHILD; CHILDHOOD CANCER; CLINICAL ARTICLE; COMPUTED TOMOGRAPHY SCANNER; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIAGNOSTIC TEST ACCURACY STUDY; DISTANT METASTASIS; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; INFANT; INTERMETHOD COMPARISON; LYMPH NODE METASTASIS; MALE; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; PREDICTIVE VALUE; RETROSPECTIVE STUDY; RHABDOMYOSARCOMA; SENSITIVITY AND SPECIFICITY; TREATMENT RESPONSE; WHOLE BODY CT; ADOLESCENT; ADULT; PATHOLOGY; PRESCHOOL CHILD; SCINTISCANNING; TIME; TREATMENT OUTCOME;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; INFANT; LYMPHATIC METASTASIS; MALE; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; RETROSPECTIVE STUDIES; RHABDOMYOSARCOMA; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84865727180     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/MNM.0b013e328356741f     Document Type: Article

References (18)

1. Paulino AC, Okcu MF. Rhabdomyosarcoma. Curr Probl Cancer 2008; 32:7-34.
2. Meza JL, Anderson J, Pappo AS, Meyer WH. Children's Oncology Group. Analysis of prognostic factors in patients with nonmetastatic rhabdomyosarcoma treated on intergroup rhabdomyosarcoma studies III and IV: the Children's Oncology Group. J Clin Oncol 2006; 24: 3844-3851. (Pubitemid 46630730)
3. Dantonello TM, Int-Veen C, Harms D, Leuschner I, Schmidt BF, Herbst M, et al. Cooperative trial CWS-91 for localized soft tissue sarcoma in children, adolescents, and young adults. J Clin Oncol 2009; 27: 1446-1455.
4. Dantonello TM, Int-Veen C, Winkler P, Leuschner I, Schuck A, Schmidt BF, et al. Initial patient characteristics can predict pattern and risk of relapse in localized rhabdomyosarcoma. J Clin Oncol 2008; 26:406-413. (Pubitemid 351171692)
5. Ricard F, Cimarelli S, Deshayes E, Mognetti T, Thiesse P, Giammarile F. Additional benefit of F-18 FDG PET/CT in the staging and follow-up of pediatric rhabdomyosarcoma. Clin Nucl Med 2011; 36:672-677.
6. Tateishi U, Hosono A, Makimoto A, Nakamoto Y, Kaneta T, Fukuda H, et al. Comparative study of FDG PET/CT and conventional imaging in the staging of rhabdomyosarcoma. Ann Nucl Med 2009; 23:155-161.
7. Völker T, Denecke T, Steffen I, Misch D, Schönberger S, Plotkin M, et al. Positron emission tomography for staging of pediatric sarcoma patients: results of a prospective multicenter trial. J Clin Oncol 2007; 25: 5435-5441. (Pubitemid 350232220)
8. Baum SH, Frühwald M, Rahbar K, Wessling J, Schober O, Weckesser M. Contribution of PET/CT to prediction of outcome in children and young adults with rhabdomyosarcoma. J Nucl Med 2011; 52: 1535-1540.
9. Gallamini A, Rigacci L, Merli F, Nassi L, Bosi A, Capodanno I, et al. The predictive value of positron emission tomography scanning performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkin's disease. Haematologica 2006; 91:475-481.
10. Schelling M, Avril N, Nährig J, Kuhn W, Römer W, Sattler D, et al. Positron emission tomography using [18F]fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer. J Clin Oncol 2000; 18:1689-1695. (Pubitemid 30220547)
11. Klem ML, Grewal RK,Wexler LH, Schöder H, Meyers PA,Wolden SL. PET for staging in rhabdomyosarcoma: an evaluation of PET as an adjunct to current staging tools. J Pediatr Hematol Oncol 2007; 29:9-14. (Pubitemid 46143019)
12. Evilevitch V, Weber WA, Tap WD, Allen-Auerbach M, Chow K, Nelson SD, et al. Reduction of glucose metabolic activity is more accurate than change in size at predicting histopathologic response to neoadjuvant therapy in high-grade soft-tissue sarcomas. Clin Cancer Res 2008; 14:715-720. (Pubitemid 351231152)
13. Nanni C, Marzola MC, Rubello D, Fanti S. Positron emission tomography for the evaluation of soft-tissue sarcomas and bone sarcomas. Eur J Nucl Med Mol Imaging 2009; 36:1940-1943.
14. Schuetze SM, Rubin BP, Vernon C, Hawkins DS, Bruckner JD, Conrad EU III, Eary JF. Use of positron emission tomography in localized extremity soft tissue sarcoma treated with neoadjuvant chemotherapy. Cancer 2005; 103:339-348. (Pubitemid 40129294)
15. Lucas JD, O'Doherty MJ, Cronin BF, Marsden PK, Lodge MA, McKee PH, Smith MA. Prospective evaluation of soft tissue masses and sarcomas using fluorodeoxyglucose positron emission tomography. Br J Surg 1999; 86:550-556. (Pubitemid 29195057)
16. Franzius C, Bielack S, Flege S, Sciuk J, Jürgens H, Schober O. Prognostic significance of (18)F-FDG and (99m)Tc-methylenediphosphonate uptake in primary osteosarcoma. J Nucl Med 2002; 43:1012-1017. (Pubitemid 34847923)
17. Hawkins DS, Schuetze SM, Butrynski JE, Rajendran JG, Vernon CB, Conrad EU III, Eary JF. [18F]Fluorodeoxyglucose positron emission tomography predicts outcome for Ewing sarcoma family of tumors. J Clin Oncol 2005; 23:8828-8834. (Pubitemid 46211529)
18. Denecke T, Hundsdörfer P, Misch D, Steffen IG, Schönberger S, Furth C, et al. Assessment of histological response of paediatric bone sarcomas using FDG PET in comparison to morphological volume measurement and standardized MRI parameters. Eur J Nucl Med Mol Imaging 2010; 37:1842-1853.